Acute erythroid leukemia

From Wikipedia the free encyclopedia

Acute erythrocyte leukemia
Other namesDi Guglielmo syndrome
Bone marrow smear from a case of erythroleukemia
SpecialtyHematology, oncology

Acute erythrocyte leukemia (AEL) is an extremely rare form of acute myeloid leukemia (less than 1% of AML cases[1]) which is characterized by neoplastic proliferation of erythroid cells with features of maturation arrest (increased erythroblasts) and high prevalence of biallelic TP53 alterations. It is defined as type "M6" under the FAB classification.

Signs and symptoms

[edit]

The most common symptoms of AEL are related to pancytopenia (a shortage of all types of blood cells), including fatigue, infections, and mucocutaneous bleeding.[2] Almost half of people with AEL exhibit weight loss, fever and night sweats at the time of diagnosis.[2] Almost all people with AEL are anemic, and 77% have a hemoglobin level under 10.0 g/dl.[2] Signs of thrombocytopenia are found in about half of people with AEL.[2]

Causes

[edit]

The causes of AEL are unknown.[3] Prior to a 2008 reclassification by the World Health Organization, cases that evolved from myelodysplastic syndromes, myeloproliferative neoplasms, chemotherapy for other cancers or exposure to toxins were defined as secondary AEL.[1] These cases are now likely to instead be classified as acute myeloid leukemia with myelodysplasia-related changes or therapy-related AML.[1] +

Diagnosis

[edit]

Acute erythroid leukemias can be classified as follows:

M6a (Erythroleukemia)

[edit]

50% or more of all nucleated bone marrow cells are erythroblasts, dyserythropoiesis is prominent and 20% or more of the remaining cells (non- erythroid) are myeloblasts.[4][5]

M6b (Pure erythroid leukemia)

[edit]

In rare cases the erythroid lineage is the only obvious component of an acute leukemia; a myeloblast component is not apparent. The erythroid component consists predominantly or exclusively of proerythroblasts and early basophilic erythroblasts. These cells may constitute 90% or more of the marrow elements. Despite this lack of myeloblasts, these cases should be considered acute leukemias. In a WHO proposal the blastic leukemias that are limited to the erythroid series are designated pure erythroid malignancies.[6]

M6c (Erythroleukemia and Pure erythroid leukemia)

[edit]

Myeloblast- and proerythroblast-rich mixed variant.[7]

Treatment

[edit]

Treatment for erythroleukemia generally follows that for other types of AML, not otherwise specified.[1] It consists of chemotherapy, frequently consisting of cytarabine, daunorubicin, and idarubicin.[8] It can also involve bone marrow transplantation.[1]

Prognosis

[edit]

Information on prognosis is limited by the rarity of the condition. Prognosis appears to be no different from AML in general, taking into account other risk factors.[9][10] Acute erythroid leukemia (M6) has a relatively poor prognosis. A 2010 study of 124 patients found a median overall survival of 8 months.[10] A 2009 study on 91 patients found a median overall survival for erythroleukemia patients of 36 weeks, with no statistically significant difference to other AML patients. AEL patients did have a significantly shorter disease-free survival period, a median of 32 weeks, but this effect was explained by other prognostic factors. That is, AEL is often associated with other risk factors, like monosomal karyotypes and a history of myelodysplastic syndrome.[9] Prognosis is worse in elderly patients, those with a history of myelodysplastic syndrome, and in patients who had previously received chemotherapy for the treatment of a different neoplasm.[1][11]

Epidemiology

[edit]

Acute erythroid leukemia is rare, accounting for only 3–5% of all acute myeloid leukemia cases.[2] One study estimated an occurrence rate of 0.077 cases per 100,000 people each year.[12] 64–70% of people with this condition are male, and most are elderly, with a median age of 65.[2]

History

[edit]

The first known case of acute erythroid leukemia was described in 1912 by M. Copelli under the name erythromatosis.[2][13] In 1917, Italian hematologist Giovanni Di Guglielmo (1886–1962), expanded on the description, coining the name "eritroleucemia" (Italian for erythroleukemia).[2][14] Di Guglielmo was the first to recognize the leukemic nature of the condition, and it is sometimes referred to as Di Guglielmo's syndrome in recognition of his work.[2] Ernst Neumark was widely credited for introducing Di Guglielmo's syndrome to English pathology.[15]

Chris Squire, bassist from the progressive rock group Yes, died from complications related to acute erythroid leukemia on June 27, 2015.[16]

References

[edit]
  1. ^ a b c d e f Zuo Z, Polski JM, Kasyan A, Medeiros LJ (2010). "Acute erythroid leukemia". Arch. Pathol. Lab. Med. 134 (9): 1261–70. doi:10.5858/2009-0350-RA.1. PMID 20807044.
  2. ^ a b c d e f g h i Santos FP, Bueso-Ramos CE, Ravandi F (2010). "Acute erythroleukemia: diagnosis and management". Expert Rev Hematol. 3 (6): 705–18. doi:10.1586/ehm.10.62. PMID 21091147. S2CID 8987729.
  3. ^ Naiem F, Rao PN (2009). "Acute Myeloid Leukemia". Hematopathology: Morphology, Immunophenotype, Cytogenetics, and Molecular Approaches. Academic Press. p. 236. ISBN 978-0-08-091948-5.
  4. ^ Schwab, Manfred (2011-09-23). Encyclopedia of Cancer. Springer Science & Business Media. p. 1313. ISBN 978-3-642-16482-8.
  5. ^ Cheng, Liang; Bostwick, David G. (2011-03-18). Essentials of Anatomic Pathology. Springer Science & Business Media. p. 764. ISBN 978-1-4419-6043-6.
  6. ^ Armitage, James O. (2004). Atlas of Clinical Hematology. Lippincott Williams & Wilkins. p. 148. ISBN 978-0-7817-5128-5.
  7. ^ Raghavan, Derek; Brecher, Martin L.; Johnson, David H.; Meropol, Neal J.; Moots, Paul L.; Rose, Peter G. (2006-07-11). Textbook of Uncommon Cancer. John Wiley & Sons. p. 546. ISBN 978-0-470-03055-4.
  8. ^ Erythroleukemia ~treatment at eMedicine
  9. ^ a b Santos FP, Faderl S, Garcia-Manero G, et al. (December 2009). "Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution". Leukemia. 23 (12): 2275–80. doi:10.1038/leu.2009.181. PMC 4217206. PMID 19741728.
  10. ^ a b Hasserjian RP, Zuo Z, Garcia C, Tang G, Kasyan A, Luthra R, Abruzzo LV, Kantarjian HM, Medeiros LJ, Wang SA (2010). "Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification". Blood. 115 (10): 1985–92. doi:10.1182/blood-2009-09-243964. PMC 2942006. PMID 20040759.
  11. ^ Orazi, Attilio; O'Malley, Dennis P.; Arber, Daniel A. (2006-07-20). Illustrated Pathology of the Bone Marrow. Cambridge University Press. p. 59. ISBN 978-1-139-45552-7.
  12. ^ Wells AW, Bown N, Reid MM, Hamilton PJ, Jackson GH, Taylor PR (2001). "Erythroleukaemia in the north of England: a population based study". J. Clin. Pathol. 54 (8): 608–12. doi:10.1136/jcp.54.8.608. PMC 1731487. PMID 11477115.
  13. ^ Kasyan A, Medeiros LJ, Zuo Z, Santos FP, Ravandi-Kashani F, Miranda R, Vadhan-Raj S, Koeppen H, Bueso-Ramos CE (2010). "Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease". Mod. Pathol. 23 (8): 1113–26. doi:10.1038/modpathol.2010.96. PMC 5846338. PMID 20473273.
  14. ^ Di Guglielmo G. (1917). "Richerche di ematologia. I. Un caso di eritroleucemia. Megacariociti in circolo e loro funzione piastrinopoietico". Folia Medica (Pavia). 13: 386.
  15. ^ "Obituary Notices" (PDF). British Medical Journal. 1967-07-29. Retrieved 2022-03-03.
  16. ^ "Yes bass guitarist Chris Squire dies aged 67". BBC News. 28 June 2015. Retrieved 22 February 2020.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Acute_erythroid_leukemia&oldid=1248221177"